Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference

Neuropsychopharmacology

Volumn 32, Issue 12, 2007, Pages 2601-2610

  Felszeghy, Klara ^a,c   Espinosa, José Manuel ^a,d   Scarna, Hélène ^b   Bérod, Anne ^b   Rostène, William ^a   Pélaprat, Didier ^a,e  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ LYON 1   (France)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITÉ BORDEAUX 1   (France)

^e CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

Cocaine; Conditioned place preference; Locomotion; Neurotensin receptor antagonist; Sensitization

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; COCAINE; NEUROTENSIN RECEPTOR ANTAGONIST; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CONTROL; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROVOCATION TEST; RAT; TREATMENT DURATION; WITHDRAWAL SYNDROME;

EID: 36248987289     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301382     Document Type: Article

References (73)

1. Azzi M, Betancur C, Sillaber I, Spanagel C, Rostène W, Bérod A (1998). Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems. J Neurochem 71: 1158-1167.
2. Baker DA, Fuchs RA, Specio SE, Khroyan TV, Neisewander JL (1998). Effects of intraaccumbens administration of SCH-23390 on cocaine-induced locomotion and conditioned place preference. Synapse 30: 181-193.
3. Baptista MA, Martin-Fardon R, Weiss F (2004). Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. J Neurosci 24: 4723-4727.
4. Bardo MT, Bevins RA (2000). Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153: 31-43.
5. Bartlett EB, Chapman B, Hallin E, Angrist B (1997). Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability? Neuropsychopharmacology 16: 77-82.
6. Beinfeld MC (2003). What we know and what we need to know about the role of endogenous CCK in psychostimulant sensitization. Life Sci 73: 643-654.
7. Bérod A, Rostène W (2002). Neurotensin: an endogenous psychostimulant? Curr Opin Pharmacol 2: 93-98.
8. Betancur C, Cabrera R, de Kloet R, Pélaprat D, Rostène W (1998). Role of endogenous neurotensin in the behavior and neuroendocrine effects of cocaine. Neuropsychopharmacology 19: 322-332.
9. Binder EB, Kinkead B, Owens MJ, Nemeroff CB (2001). Neurotensin and dopamine interactions. Pharmacol Rev 53: 453-486.
10. Blackburn A, Dewar K, Bauco P, Rompré PP (2004). Excitotoxic lesions of the prefrontal cortex attenuate the potentiation of amphetamine-induced locomotion by repeated neurotensin receptor activation. Brain Res 998: 184-193.
11. Borgland SL, Malenka RC, Bonci A (2004). Acute and chronic cocaine-induced potentiation of synaptic strength in the ventral tegmental area: electrophysiological and behavioral correlates in individual rats. J Neurosci 24: 7482-7490.
12. Boudin H, Pélaprat D, Rostène W, Beaudet A (1996). Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. J Comp Neurol 373: 76-89.
13. Carraway R, Leeman SE (1973). The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalamus. J Biol Chem 248: 6854-6861.
14. Costa FG, Frussa-Filho R, Felicio LF (2001). The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice. Eur J Pharmacol 428: 97-103.
15. Crombag HS, Badiani A, Chan J, Dell'Orco J, Dineen SP, Robinson TE (2001). The ability of environmental context to facilitate psychomotor sensitization to amphetamine can be dissociated from its effect on acute drug responsiveness and on conditioned responding. Neuropsychopharmacology 24: 680-690.
16. De Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M (2002). Pharmacological treatment of cocaine dependence: a systematic review. Addiction 97: 931-949.
17. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J et al (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7: 1099-1100.
18. Dewey SL, Morgan AE, Ashby Jr CR, Horan B, Kushner SA, Logan J et al (1998). A novel strategy for the treatment of cocaine addiction. Synapse 30: 119-129.
19. Elliott PJ, Nemeroff CB (1986). Repeated neurotensin administration in the ventral tegmental area: effects on baseline and D-amphetamine-induced locomotor activity. Neurosci Lett 68: 239-244.
20. Ervin GN, Birkemo LS, Nemeroff CB, Prange Jr AJ (1981). Neurotensin blocks certain amphetamine-induced behaviors. Nature 291: 73-76.
21. Fantegrossi WE, Ko MCH, Woods JH, Richelson E (2005). Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkey. Pharmacol Biochem Behav 80: 341-349.
22. Fatigati MD, Anderson RM, Rompré PP (2000). Effects of prefrontal cortex microinjection of neurotensin-(8-13) on midbrain dopamine and non-dopamine cell firing. Brain Res 876: 196-200.
23. Ferrario CR, Gorny G, Crombag HS, Kolb B, Robinson TE (2005). Neural and behavioral plasticity associated with the transition from controlled to escalated cocaine use. Biol Psychiatry 58: 751-759.
24. Ford APDW, Marsden CA (1990). In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and D-Tryp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat. Brain Res 534: 243-250.
25. Gawin FH (1991). Cocaine addiction: psychology and neurophysiology. Science 251: 1580-1586.
26. Gawin FH, Ellinwood Jr EH (1989). Cocaine dependence. Ann Rev Med 40: 149-161.
27. Geisler S, Bérod A, Zahm DS, Rostène W (2006). Brain neurotensin, psychostimulants, and stress - emphasis on neuroanatomical substrates. Peptides 27: 2364-2384.
28. Geisler S, Zahm DS (2006). Neurotensin afferents of the ventral tegmental area in the rat: (1) re-examination of their origins and (2) responses to acute psychostimulant and antipsychotic drug administration. Eur J Neurosci 24: 116-134.
29. Gendron L, Perron A, Payet MD, Gallo-Payet N, Sarret P, Beaudet A (2004). Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signalregulated kinases 1/2. Mol Pharmacol 66: 1421-1430.
30. Glimcher PW, Govino AA, Hoebel BG (1987). Neurotensin self-injection in the ventral tegmental area. Brain Res 400: 147-150.
31. Glimcher PW, Margolin DH, Giovino AA, Hoebel BG (1984). Neurotensin: a new 'reward peptide'. Brain Res 291: 119-124.
32. Gully D, Canton M, Boigegrain R, Jeanjean R, Molimard JC, Poncelet M et al (1993). Biochemical and pharmacological profile of a potent and selective neurotensin receptor antagonist. Proc Natl Acad Sci USA 90: 65-69.
33. Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M et al (1997). Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther 280: 802-812.
34. Horger BA, Taylor JE, Elsworth JD, Roth RH (1994). Preexposure to, but not cotreatment with, the neurotensin antagonist SR 48692 delays the development of cocaine sensitization. Neuropsychopharmacology 11: 215-222.
35. Jaffe JH, Cascella NG, Kumor KM, Scherer MA (1989). Cocaine-induced cocaine craving. Psychopharmacology 97: 59-64.
36. Kalivas PW, Duffy P (1990). Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J Neurosci 10: 2940-2949.
37. Kalivas PW, Stewart J (1991). Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of locomotor activity. Brain Res Rev 16: 223-244.
38. Kinkead B, Nemeroff B (2002). Neurotensin: an endogenous antipsychotic? Curr Opin Pharmacol 2: 99-103.
39. Kitabgi P (2002). Targeting neurotensin receptors with agonists or antagonists for therapeutic purposes. Curr Opin Drug Discov Dev 5: 764-776.
40. Koob GF, Sanna PP, Bloom F (1998). Neuroscience of addiction. Neuron 21: 467-476.
41. Kreek MJ, LaForge KS, Butelman E (2002). Pharmacotherapy of addictions. Nat Rev 1: 710-726.
42. Li Y, Hu XT, Berney TG, Vartanian AJ, Stine CD, Wolf ME et al (1999). Both glutamate receptor antagonists and prefrontal cortex lesions prevent induction of cocaine sensitization and associated neuroadaptations. Synapse 34: 169-180.
43. Liu Q-S, Pu L, Poo M-M (2005). Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature 437: 1027-1031.
44. Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorders. Am J Psychiatry 161: 975-984.
45. Morgan AE, Porter SP, Clarkson FA, Volkow ND, Fowler JS, Dewey SL (1997). Direct approach for attenuating cocaine's effects on extracellular dopamine: targeting the dopamine transporter. Synapse 26: 423-427.
46. Mueller D, Stewart J (2000). Cocaine-induced conditioned place preference: reinstatement by priming injections of cocaine after extinction. Behav Brain Res 115: 39-47.
47. O'Brien MS, Anthony JC (2005). Risk of becoming cocaine dependent: epidemiological estimates for the United States, 2000-2001. Neuropsychopharmacology 30: 1006-1018.
48. Panayi F, Colussi-Mas J, Lambas-Senas L, Renaud B, Scarna H, Bérod A (2005). Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization. Neuropsychopharmacology 30: 871-879.
49. Panayi F, Dorso E, Lambas-Senas L, Renaud B, Scarna H, Bérod A (2002). Chronic blockade of neurotensin receptor reduces sensitized, but not acute, behavioral response to D-amphetamine. Neuropsychopharmacology 26: 64-74.
50. Pierce RC, Kalivas PW (1997). A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 25: 192-216.
51. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG et al (1999). Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400: 371-375.
52. Post RM, Rose H (1976). Increasing effect of repetitive cocaine administration in the rat. Nature 260: 731-732.
53. Radja F, Bauco P, Rompré PP (2006). Effects of excitotoxic lesions of the medial prefrontal cortex on density of high affinity [(125)I-Tyr3] neurotensin binding sites within the ventral midbrain and striatum. Eur J Pharmacol 539: 158-163.
54. Richelson E, Boules M, Fredrickson P (2003). Neurotensin agonists: possible drugs for treatment of psychostimulant abuse. Life Sci 73: 679-690.
55. Robinson TE, Berridge KC (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18: 247-291.
56. Rompré P, Perron S (2000). Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization. Neuropharmacology 39: 1880-1892.
57. Rompré PP (1997). Repeated activation of neurotensin receptors sensitizes to the stimulant effect of amphetamine. Eur J Pharmacol 328: 131-134.
58. Rompré PP, Bauco P (2006). Neurotensin receptor activation sensitizes to the locomotor stimulant effect of cocaine: a role for NMDA receptors. Brain Res 1085: 77-86.
59. Rompré PP, Boye SM, Moisan J (1998). Activation of neurotensin receptors in the prefrontal cortex stimulates midbrain dopamine cell firing. Eur J Pharmacol 341: 169-172.
60. Rostène W, Azzi M, Boudin H, Lépée I, Souazé F, Mendez-Ubah M et al (1998). Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Ann NY Acad Sci 814: 125-140.
61. Santucci V, Gueudet C, Steinberg R, Le Fur G, Soubrié P (1997). Involvement of cortical neurotensin in the regulation of rat meso-cortico-limbic dopamine neurons: evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade. Synapse 26: 370-380.
62. Sarnyai Z, Shaham Y, Heinrichs SC (2001). The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53: 209-243.
63. Sarret P, Gendron L, Kilian P, Nguyen HM, Gallo-Payet MD, Beaudet A (2002). Pharmacology and functional properties of NTS2 neurotensin receptors in cerebellar granule cells. J Biol Chem 277: 36233-36243.
64. Soares BG, Reisser AA, Farrell M (2003). Dopamine agonists for cocaine dependence. Cochrane Database Syst Rev 2003: CD003352.
65. Sotty F, Soulière F, Brun P, Chouvet G, Steinberg R, Soubrié P et al (1998). Differential effects of neurotensin on dopamine release in the caudal and rostral nucleus accumbens: a combined in vivo electrochemical and electrophysiological study. Neuroscience 85: 1173-1182.
66. Stewart J (2000). Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatry Neurosci 25: 125-136.
67. Tzschentke TM (2000). The medial prefrontal cortex as a part of the brain reward system. Amino Acids 19: 211-219.
68. B receptor antagonist. Psychopharmacology 131: 79-85.
69. an den Brink W, van Ree JM (2003). Pharmacological treatments for heroin and cocaine addiction. Eur Neuropsychopharmacol 13: 476-487.
70. Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology 151: 99-120.
71. Vezina P, Lorrain DS, Arnold GM, Austin JD, Suto N (2002). Sensitization of midbrain dopamine neuron reactivity promotes the pursuit of amphetamine. J Neurosci 22: 4654-4662.
72. Vita N, Oury-Donat F, Chalon P, Guillemot M, Kaghat M, Bachy A et al (1998). Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur J Pharmacol 360: 265-272.
73. Yamada M, Lombet A, Forgez P, Rostene W (1998). Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptors expressed in Chinese Hamster Ovary cells. Life Sci 62: 375-380.